Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07189871 · ClinicalTrials.gov registry record · Phase 1
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
A Phase 1 study of Colorectal Cancer and Ovarian Cancer, sponsored by Radiopharm Theranostics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
- 2
- Study locations
NCT07189871 is a Phase 1 study of Colorectal Cancer and Ovarian Cancer that is actively recruiting participants, run by Radiopharm Theranostics. The registered enrollment target is 61 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT07189871, a Phase 1 study of Colorectal Cancer and Ovarian Cancer, is actively recruiting participants, sponsored by Radiopharm Theranostics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
- 2
- Study locations
Study Summary
A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Conditions Studied
Interventions
- DRUG 177Lu-BetaBart
Study Locations (2)
Michigan
- BAMF Health - Grand Rapids
Nebraska
- Nebraska Cancer Specialists - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2026-02 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07189871
The ClinicalTrials.gov registry entry for NCT07189871 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Radiopharm Theranostics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which 177Lu-BetaBart is the first listed.
NCT07189871 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Michigan, Nebraska.
Frequently Asked Questions
What is clinical trial NCT07189871 about?
NCT07189871 is a clinical study titled "177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors". A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
What is the current status of trial NCT07189871?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2026-02. Estimated completion is 2027-12.
What conditions does trial NCT07189871 study?
This clinical trial studies the following conditions: Colorectal Cancer, Ovarian Cancer, Endometrial Cancer, Cervical Cancer, TNBC - Triple-Negative Breast Cancer.
What interventions are being tested in trial NCT07189871?
The interventions under investigation include: 177Lu-BetaBart (DRUG).
Who is sponsoring clinical trial NCT07189871?
This trial is sponsored by Radiopharm Theranostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07189871 being conducted?
This trial has 2 study locations across Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.